Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets
06. Juni 2019 18:46 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug...
Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
15. April 2019 07:48 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address...
Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28. März 2019 16:01 ET
|
Achaogen, Inc.
-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic...
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019
13. März 2019 16:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine
21. Februar 2019 08:00 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
21. Februar 2019 08:00 ET
|
Achaogen, Inc.
-- ZEMDRI is the only once-daily aminoglycoside therapy FDA-approved for use in complicated urinary tract infections (cUTI) -- -- Treatment with ZEMDRI resulted in a greater than four-fold reduction...
Achaogen Announces Closing of $15 Million Underwritten Public Offering
20. Februar 2019 16:02 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences
20. Februar 2019 16:01 ET
|
Achaogen, Inc.
-- Leerink February 27, 2019 at 9:30 a.m. ET -- -- Cowen March 12, 2019 at 12:00 p.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a...
Achaogen Announces Pricing of $15 Million Underwritten Public Offering
15. Februar 2019 06:11 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Proposed Public Offering of Common Stock
14. Februar 2019 16:00 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...